1418307-30-8

Basic information

• Product Name: 4-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)-N-(4-trifluoromethyl-pyridin-2-yl)benzamide
• Synonyms: 4-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)-N-(4-trifluoromethyl-pyridin-2-yl)benzamide
• CAS NO: 1418307-30-8
• Molecular Weight: 392.186
• Mol File: 1418307-30-8.mol
• Article Data: 12

Chemical Properties

• CAS DataBase Reference: 4-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)-N-(4-trifluoromethyl-pyridin-2-yl)benzamide(CAS DataBase Reference)
• NIST Chemistry Reference: 4-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)-N-(4-trifluoromethyl-pyridin-2-yl)benzamide(1418307-30-8)
• EPA Substance Registry System: 4-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)-N-(4-trifluoromethyl-pyridin-2-yl)benzamide(1418307-30-8)

Safety Data

• Hazardous Substances Data: 1418307-30-8(Hazardous Substances Data)

Upstream product

• 180516-87-4 4-carboxyphenylboronic acid pinacol ester 
• 106447-97-6 2-amino-4-(trifluoromethyl)pyridine 
• 586-76-5 4-Bromobenzoic acid 
• 586-75-4 4-chlorobenzoyl chloride 
• 380499-68-3 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzoic acid chloride 

Downstream Products

• 1419222-77-7 methyl 1-(8-amino-1-(4-(4-(trifluoromethyl)pyridin-2-ylcarbamoyl)phenyl)imidazo[1,5-a]pyrazin-3-yl)piperidine-3-carboxylate 
• 1419222-92-6 tert-butyl 3-(4-amino-5-(4-(4-(trifluoromethyl)pyridin-2-ylcarbamoyl)phenyl)pyrrolo[1,2-f][1,2,4]triazin-7-yl)piperidine-1-carboxylate 
• 1419223-02-1 (R)-tert-butyl 3-(4-amino-3-(4-(4-(trifluoromethyl)pyridin-2-ylcarbamoyl)phenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidine-1-carboxylate 
• 1620673-97-3 4-(8-amino-3-((3R,7R,9aS)-3-methyl-4-oxooctahydropyrido[2,1-c][1,4]oxazin-7-yl)imidazo[1,5-a]pyrazin-1-yl)-N-(4-(trifluoromethyl)pyridin-2-yl)benzamide 
• 1620564-27-3 (S)-4-(8-amino-3-(3-(trifluoromethyl)-5,6,7,8-tetrahydro-[1,2,4]triazolo[4,3-a]pyridin-7-yl)imidazo[1,5-a]pyrazin-1-yl)-N-(4-(trifluoromethyl)pyridin-2-yl)benzamide 
• 1620564-28-4 (R)-4-(8-amino-3-(3-(trifluoromethyl)-5,6,7,8-tetrahydro-[1,2,4]triazolo[4,3-a]pyridin-7-yl)imidazo[1,5-a]pyrazin-1-yl)-N-(4-(trifluoromethyl)pyridin-2-yl)benzamide 
• 1620564-53-5 (R)-4-(4-((2,4-dimethoxybenzyl)amino)-1-(1-methyl-4,5,6,7-tetrahydro-1H-indazol-4-yl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl)-N-(4-(trifluoromethyl)pyridin-2-yl)benzamide 
• 1620564-54-6 (R)-4-(4-((2,4-dimethoxybenzyl)amino)-1-(2-methyl-4,5,6,7-tetrahydro-2H-indazol-4-yl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl)-N-(4-(trifluoromethyl)pyridin-2-yl)benzamide 
• 1620564-19-3 4-(8-amino-3-(4-hydroxy-1-methyl-4,5,6,7-tetrahydro-1H-indazol-4-yl)imidazo[1,5-a]pyrazin-1-yl)-N-(4-(trifluoromethyl)pyridin-2-yl)benzamide 
• 1620564-20-6 (S)-4-(8-amino-3-(4-hydroxy-1-methyl-4,5,6,7-tetrahydro-1H-indazol-4-yl)imidazo[1,5-a]pyrazin-1-yl)-N-(4-(trifluoromethyl)pyridin-2-yl)benzamide 
• 1620564-21-7 (R)-4-(8-amino-3-(4-hydroxy-1-methyl-4,5,6,7-tetrahydro-1H-indazol-4-yl)imidazo[1,5-a]pyrazin-1-yl)-N-(4-(trifluoromethyl)pyridin-2-yl)benzamide 

Relevant articles and documents

Design and synthesis of novel substituted benzyl pyrrolopyrimidine derivatives as selective BTK inhibitors for treating mantle cell lymphoma

Ibrutinib, a potent irreversible Bruton's tyrosine kinase (BTK) inhibitor, was approved by the FDA for treating mantle cell lymphoma (MCL). Although ibrutinib exhibited excellent antitumor activity, it was associated with certain adverse reactions, with o

The compounds of structure containing conjugated zincon, its pharmaceutical composition and use thereof (by machine translation)

The present invention relates to compounds having a structure containing conjugated zincon, its pharmaceutical composition and use, and in particular relates to the general formula (I) or a salt thereof to the compound represented by the, pharmaceutical compositions thereof, and its as BTK inhibitors and/or B cell activation inhibitor, for the prevention or treatment B cell activity with abnormal and/or the use of the BTK-related diseases. The compounds of lymphoma, breast cancer, liver cancer, colon cancer, gastric cancer, such as lung cancer and cervical cancer cell has better lethal effect, note has potential for the treatment of cancer and self-immune diseases related to potential. (by machine translation)

IMIDAZOPYRAZINE INHIBITORS OF BRUTON'S TYROSINE KINASE

In some embodiments, the invention relates to a BTK inhibitor or a pharmaceutically acceptable salt, cocrystal, ester, prodrug, solvate, hydrate or derivative thereof, or to pharmaceutical compositions comprising these compounds and to their use in therap